ID   DHYS_HUMAN              Reviewed;         369 AA.
AC   P49366; A8K688; M0R1I5; Q13184; Q13276; Q9UDG0;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   07-APR-2021, entry version 199.
DE   RecName: Full=Deoxyhypusine synthase;
DE            Short=DHS;
DE            EC=2.5.1.46 {ECO:0000269|PubMed:30661771};
GN   Name=DHPS; Synonyms=DS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RX   PubMed=7673224; DOI=10.1074/jbc.270.38.22386;
RA   Joe Y.A., Wolff E.C., Park M.H.;
RT   "Cloning and expression of human deoxyhypusine synthase cDNA. Structure-
RT   function studies with the recombinant enzyme and mutant proteins.";
RL   J. Biol. Chem. 270:22386-22392(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RC   TISSUE=Blood;
RX   PubMed=8549832; DOI=10.1016/0014-5793(95)01456-x;
RA   Bevec D., Kappel B., Jaksche H., Csonga R., Hauber J., Klier H.,
RA   Steinkasserer A.;
RT   "Molecular characterization of a cDNA encoding functional human
RT   deoxyhypusine synthase and chromosomal mapping of the corresponding gene
RT   locus.";
RL   FEBS Lett. 378:195-198(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT).
RX   PubMed=8615810; DOI=10.1042/bj3150429;
RA   Yan Y.P., Tao Y., Chen K.Y.;
RT   "Molecular cloning and functional expression of human deoxyhypusine
RT   synthase cDNA based on expressed sequence tag information.";
RL   Biochem. J. 315:429-434(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9666110; DOI=10.1016/s0378-1119(98)00254-6;
RA   Mantuano E., Trettel F., Olsen A.S., Lennin G., Frontali M., Jodice C.;
RT   "Localization and genomic structure of human deoxyhypusine synthase gene on
RT   chromosome 19p13.2-distal 19p13.1.";
RL   Gene 215:153-157(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Brain;
RX   PubMed=9110174; DOI=10.1101/gr.7.4.353;
RA   Yu W., Andersson B., Worley K.C., Muzny D.M., Ding Y., Liu W.,
RA   Ricafrente J.Y., Wentland M.A., Lennon G., Gibbs R.A.;
RT   "Large-scale concatenation cDNA sequencing.";
RL   Genome Res. 7:353-358(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Neuroblastoma;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 184-189; 192-204; 206-232 AND 278-296 (ISOFORM LONG).
RC   TISSUE=Cervix carcinoma;
RX   PubMed=7750572; DOI=10.1016/0014-5793(95)00394-o;
RA   Klier H., Csonga R., Steinkasserer A., Woehl T., Lottspeich F., Eder J.;
RT   "Purification and characterization of human deoxyhypusine synthase from
RT   HeLa cells.";
RL   FEBS Lett. 364:207-210(1995).
RN   [12]
RP   MUTAGENESIS OF LYS-287 AND LYS-329, SUBUNIT, AND ACTIVE SITE.
RX   PubMed=9405486; DOI=10.1074/jbc.272.51.32679;
RA   Joe Y.A., Wolff E.C., Lee Y.B., Park M.H.;
RT   "Enzyme-substrate intermediate at a specific lysine residue is required for
RT   deoxyhypusine synthesis. The role of Lys329 in human deoxyhypusine
RT   synthase.";
RL   J. Biol. Chem. 272:32679-32685(1997).
RN   [13]
RP   MUTAGENESIS OF ASN-106; SER-109; GLU-137; ASP-238; ASP-243; HIS-288;
RP   TYR-305; ASP-313; ASP-316; SER-317; GLU-323; TRP-327 AND ASP-342.
RX   PubMed=11311149; DOI=10.1042/bj3550841;
RA   Lee C.H., Um P.Y., Park M.H.;
RT   "Structure-function studies of human deoxyhypusine synthase: identification
RT   of amino acid residues critical for the binding of spermidine and NAD.";
RL   Biochem. J. 355:841-849(2001).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-78, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-78, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, VARIANTS NEDSSWI SER-173 AND
RP   305-TYR-ILE-306 DEL, CHARACTERIZATION OF VARIANTS NEDSSWI SER-173 AND
RP   305-TYR-ILE-306 DEL, AND INVOLVEMENT IN NEDSSWI.
RX   PubMed=30661771; DOI=10.1016/j.ajhg.2018.12.017;
RA   Ganapathi M., Padgett L.R., Yamada K., Devinsky O., Willaert R., Person R.,
RA   Au P.B., Tagoe J., McDonald M., Karlowicz D., Wolf B., Lee J., Shen Y.,
RA   Okur V., Deng L., LeDuc C.A., Wang J., Hanner A., Mirmira R.G., Park M.H.,
RA   Mastracci T.L., Chung W.K.;
RT   "Recessive rare variants in deoxyhypusine synthase, an enzyme involved in
RT   the synthesis of hypusine, are associated with a neurodevelopmental
RT   disorder.";
RL   Am. J. Hum. Genet. 104:287-298(2019).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH NAD, AND SUBUNIT.
RX   PubMed=9493264; DOI=10.1016/s0969-2126(98)00004-5;
RA   Liao D.-I., Wolff E.C., Park M.H., Davies D.R.;
RT   "Crystal structure of the NAD complex of human deoxyhypusine synthase: an
RT   enzyme with a ball-and-chain mechanism for blocking the active site.";
RL   Structure 6:23-32(1998).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) IN COMPLEXES WITH NAD AND
RP   COMPETITIVE INHIBITOR, IDENTIFICATION BY MASS SPECTROMETRY, AND SUBUNIT.
RX   PubMed=15100216; DOI=10.1074/jbc.m404095200;
RA   Umland T.C., Wolff E.C., Park M.H., Davies D.R.;
RT   "A new crystal structure of deoxyhypusine synthase reveals the
RT   configuration of the active enzyme and of an enzyme.NAD.inhibitor ternary
RT   complex.";
RL   J. Biol. Chem. 279:28697-28705(2004).
CC   -!- FUNCTION: Catalyzes the NAD-dependent oxidative cleavage of spermidine
CC       and the subsequent transfer of the butylamine moiety of spermidine to
CC       the epsilon-amino group of a critical lysine residue of the eIF-5A
CC       precursor protein to form the intermediate deoxyhypusine residue
CC       (PubMed:30661771). This is the first step of the post-translational
CC       modification of that lysine into an unusual amino acid residue named
CC       hypusine. Hypusination is unique to mature eIF-5A factor and is
CC       essential for its function. {ECO:0000269|PubMed:30661771}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[eIF5A protein]-L-lysine + spermidine = [eIF5A protein]-
CC         deoxyhypusine + propane-1,3-diamine; Xref=Rhea:RHEA:33299, Rhea:RHEA-
CC         COMP:10143, Rhea:RHEA-COMP:10144, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57484, ChEBI:CHEBI:57834, ChEBI:CHEBI:82657; EC=2.5.1.46;
CC         Evidence={ECO:0000269|PubMed:30661771};
CC   -!- COFACTOR:
CC       Name=NAD(+); Xref=ChEBI:CHEBI:57540;
CC   -!- PATHWAY: Protein modification; eIF5A hypusination.
CC       {ECO:0000269|PubMed:30661771}.
CC   -!- SUBUNIT: Homotetramer formed by a dimer of dimers.
CC       {ECO:0000269|PubMed:15100216, ECO:0000269|PubMed:9405486,
CC       ECO:0000269|PubMed:9493264}.
CC   -!- INTERACTION:
CC       P49366; P49366: DHPS; NbExp=4; IntAct=EBI-741925, EBI-741925;
CC       P49366; P63241: EIF5A; NbExp=6; IntAct=EBI-741925, EBI-373150;
CC       P49366; Q9GZV4: EIF5A2; NbExp=7; IntAct=EBI-741925, EBI-748028;
CC       P49366; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-741925, EBI-739832;
CC       P49366; P27361: MAPK3; NbExp=9; IntAct=EBI-741925, EBI-73995;
CC       P49366; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-741925, EBI-16439278;
CC       P49366; Q9GZT8: NIF3L1; NbExp=3; IntAct=EBI-741925, EBI-740897;
CC       P49366; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-741925, EBI-741158;
CC       P49366; Q6ZVK8: NUDT18; NbExp=3; IntAct=EBI-741925, EBI-740486;
CC       P49366; P26367: PAX6; NbExp=3; IntAct=EBI-741925, EBI-747278;
CC       P49366; Q9HD43: PTPRH; NbExp=3; IntAct=EBI-741925, EBI-1267176;
CC       P49366; O00194: RAB27B; NbExp=6; IntAct=EBI-741925, EBI-10179046;
CC       P49366; P09455: RBP1; NbExp=3; IntAct=EBI-741925, EBI-2623483;
CC       P49366; Q04864: REL; NbExp=3; IntAct=EBI-741925, EBI-307352;
CC       P49366; Q04864-2: REL; NbExp=3; IntAct=EBI-741925, EBI-10829018;
CC       P49366; P32969: RPL9P9; NbExp=11; IntAct=EBI-741925, EBI-358122;
CC       P49366; Q7L8A9: VASH1; NbExp=3; IntAct=EBI-741925, EBI-10256546;
CC       P49366; P52744: ZNF138; NbExp=3; IntAct=EBI-741925, EBI-10746567;
CC       P49366; P52744-2: ZNF138; NbExp=3; IntAct=EBI-741925, EBI-10213071;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Long;
CC         IsoId=P49366-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P49366-2; Sequence=VSP_001351;
CC       Name=3;
CC         IsoId=P49366-3; Sequence=VSP_047564;
CC   -!- DISEASE: Neurodevelopmental disorder with seizures and speech and
CC       walking impairment (NEDSSWI) [MIM:618480]: An autosomal recessive
CC       disorder characterized by global developmental delay with intellectual
CC       disability and poor speech acquisition, and walking difficulties due to
CC       hypotonia, hypertonia, spasticity, or poor coordination. Additional
CC       features include seizures, mild dysmorphic features, and variable short
CC       stature. {ECO:0000269|PubMed:30661771}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform Short]: Inactive. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the deoxyhypusine synthase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AL520040; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L39068; AAA86282.1; -; mRNA.
DR   EMBL; U40579; AAA96151.1; -; mRNA.
DR   EMBL; U32178; AAB02179.1; -; mRNA.
DR   EMBL; U26266; AAB02175.1; -; mRNA.
DR   EMBL; AJ001701; CAA04940.1; -; Genomic_DNA.
DR   EMBL; AJ001702; CAA04940.1; JOINED; Genomic_DNA.
DR   EMBL; AJ001703; CAA04940.1; JOINED; Genomic_DNA.
DR   EMBL; AJ001704; CAA04940.1; JOINED; Genomic_DNA.
DR   EMBL; U79262; AAB50208.1; -; mRNA.
DR   EMBL; AL520040; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK291553; BAF84242.1; -; mRNA.
DR   EMBL; AC010422; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471106; EAW84288.1; -; Genomic_DNA.
DR   EMBL; BC000333; AAH00333.1; -; mRNA.
DR   EMBL; BC014016; AAH14016.1; -; mRNA.
DR   CCDS; CCDS12276.1; -. [P49366-1]
DR   CCDS; CCDS12277.1; -. [P49366-2]
DR   CCDS; CCDS59354.1; -. [P49366-3]
DR   PIR; S68692; S68692.
DR   RefSeq; NP_001193903.1; NM_001206974.1. [P49366-3]
DR   RefSeq; NP_001921.1; NM_001930.3. [P49366-1]
DR   RefSeq; NP_037538.1; NM_013406.2. [P49366-2]
DR   RefSeq; XP_011526072.1; XM_011527770.1.
DR   PDB; 1DHS; X-ray; 2.20 A; A=9-369.
DR   PDB; 1RLZ; X-ray; 2.15 A; A=1-369.
DR   PDB; 1ROZ; X-ray; 2.21 A; A/B=1-369.
DR   PDB; 1RQD; X-ray; 3.00 A; A/B=1-369.
DR   PDB; 6P4V; X-ray; 1.65 A; A/B=1-369.
DR   PDB; 6PGR; X-ray; 1.95 A; A/B=1-369.
DR   PDB; 6WKZ; X-ray; 2.23 A; A/B=1-369.
DR   PDB; 6WL6; X-ray; 2.12 A; A/B=1-369.
DR   PDB; 6XXH; X-ray; 1.52 A; A/B=1-369.
DR   PDB; 6XXI; X-ray; 1.68 A; A/B=1-369.
DR   PDB; 6XXJ; X-ray; 1.41 A; A/B=1-369.
DR   PDB; 6XXK; X-ray; 1.65 A; A/B=1-369.
DR   PDB; 6XXL; X-ray; 1.69 A; A/B=1-369.
DR   PDB; 6XXM; X-ray; 1.67 A; A/B=1-369.
DR   PDBsum; 1DHS; -.
DR   PDBsum; 1RLZ; -.
DR   PDBsum; 1ROZ; -.
DR   PDBsum; 1RQD; -.
DR   PDBsum; 6P4V; -.
DR   PDBsum; 6PGR; -.
DR   PDBsum; 6WKZ; -.
DR   PDBsum; 6WL6; -.
DR   PDBsum; 6XXH; -.
DR   PDBsum; 6XXI; -.
DR   PDBsum; 6XXJ; -.
DR   PDBsum; 6XXK; -.
DR   PDBsum; 6XXL; -.
DR   PDBsum; 6XXM; -.
DR   SMR; P49366; -.
DR   BioGRID; 108070; 72.
DR   IntAct; P49366; 36.
DR   MINT; P49366; -.
DR   STRING; 9606.ENSP00000210060; -.
DR   ChEMBL; CHEMBL4415; -.
DR   DrugBank; DB03639; 1-Guanidinium-7-Aminoheptane.
DR   iPTMnet; P49366; -.
DR   MetOSite; P49366; -.
DR   PhosphoSitePlus; P49366; -.
DR   BioMuta; DHPS; -.
DR   DMDM; 1352267; -.
DR   EPD; P49366; -.
DR   jPOST; P49366; -.
DR   MassIVE; P49366; -.
DR   MaxQB; P49366; -.
DR   PaxDb; P49366; -.
DR   PeptideAtlas; P49366; -.
DR   PRIDE; P49366; -.
DR   ProteomicsDB; 55996; -. [P49366-1]
DR   ProteomicsDB; 55997; -. [P49366-2]
DR   Antibodypedia; 1964; 308 antibodies.
DR   DNASU; 1725; -.
DR   Ensembl; ENST00000210060; ENSP00000210060; ENSG00000095059. [P49366-1]
DR   Ensembl; ENST00000351660; ENSP00000221303; ENSG00000095059. [P49366-2]
DR   Ensembl; ENST00000594424; ENSP00000471886; ENSG00000095059. [P49366-3]
DR   GeneID; 1725; -.
DR   KEGG; hsa:1725; -.
DR   UCSC; uc002mug.3; human. [P49366-1]
DR   CTD; 1725; -.
DR   DisGeNET; 1725; -.
DR   GeneCards; DHPS; -.
DR   HGNC; HGNC:2869; DHPS.
DR   HPA; ENSG00000095059; Low tissue specificity.
DR   MalaCards; DHPS; -.
DR   MIM; 600944; gene.
DR   MIM; 618480; phenotype.
DR   neXtProt; NX_P49366; -.
DR   OpenTargets; ENSG00000095059; -.
DR   PharmGKB; PA27329; -.
DR   VEuPathDB; HostDB:ENSG00000095059.15; -.
DR   eggNOG; KOG2924; Eukaryota.
DR   GeneTree; ENSGT00390000008063; -.
DR   HOGENOM; CLU_039781_0_0_1; -.
DR   InParanoid; P49366; -.
DR   PhylomeDB; P49366; -.
DR   TreeFam; TF300625; -.
DR   BioCyc; MetaCyc:HS01810-MONOMER; -.
DR   BRENDA; 2.5.1.46; 2681.
DR   PathwayCommons; P49366; -.
DR   Reactome; R-HSA-204626; Hypusine synthesis from eIF5A-lysine.
DR   SABIO-RK; P49366; -.
DR   UniPathway; UPA00354; -.
DR   BioGRID-ORCS; 1725; 582 hits in 996 CRISPR screens.
DR   ChiTaRS; DHPS; human.
DR   EvolutionaryTrace; P49366; -.
DR   GeneWiki; DHPS; -.
DR   GenomeRNAi; 1725; -.
DR   Pharos; P49366; Tbio.
DR   PRO; PR:P49366; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P49366; protein.
DR   Bgee; ENSG00000095059; Expressed in right hemisphere of cerebellum and 237 other tissues.
DR   ExpressionAtlas; P49366; baseline and differential.
DR   Genevisible; P49366; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0034038; F:deoxyhypusine synthase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008612; P:peptidyl-lysine modification to peptidyl-hypusine; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0008216; P:spermidine metabolic process; IDA:UniProtKB.
DR   GO; GO:0006412; P:translation; TAS:ProtInc.
DR   Gene3D; 3.40.910.10; -; 1.
DR   InterPro; IPR002773; Deoxyhypusine_synthase.
DR   InterPro; IPR036982; Deoxyhypusine_synthase_sf.
DR   InterPro; IPR029035; DHS-like_NAD/FAD-binding_dom.
DR   PANTHER; PTHR11703; PTHR11703; 1.
DR   Pfam; PF01916; DS; 1.
DR   SUPFAM; SSF52467; SSF52467; 1.
DR   TIGRFAMs; TIGR00321; dhys; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Direct protein sequencing;
KW   Disease variant; Hypusine biosynthesis; Mental retardation; NAD;
KW   Phosphoprotein; Reference proteome; Transferase.
FT   CHAIN           1..369
FT                   /note="Deoxyhypusine synthase"
FT                   /id="PRO_0000134469"
FT   NP_BIND         105..109
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:9493264"
FT   NP_BIND         131..133
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:9493264"
FT   NP_BIND         308..309
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:9493264"
FT   NP_BIND         342..343
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:9493264"
FT   REGION          136..137
FT                   /note="Spermidine binding"
FT                   /evidence="ECO:0000305"
FT   REGION          314..316
FT                   /note="Spermidine binding"
FT                   /evidence="ECO:0000305"
FT   REGION          323..329
FT                   /note="Spermidine binding"
FT                   /evidence="ECO:0000305"
FT   ACT_SITE        329
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:9405486"
FT   BINDING         137
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:9493264"
FT   BINDING         238
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:9493264"
FT   BINDING         243
FT                   /note="Spermidine"
FT                   /evidence="ECO:0000305"
FT   BINDING         283
FT                   /note="NAD; via amide nitrogen"
FT                   /evidence="ECO:0000269|PubMed:9493264"
FT   BINDING         288
FT                   /note="Spermidine"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         78
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:20068231"
FT   VAR_SEQ         1..68
FT                   /note="MEGSLEREAPAGALAAVLKHSSTLPPESTQVRGYDFNRGVNYRALLEAFGTT
FT                   GFQATNFGRAVQQVNA -> MPIIPAFWEAEAGGSREEEFETSLAN (in isoform
FT                   3)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_047564"
FT   VAR_SEQ         262..308
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:8615810"
FT                   /id="VSP_001351"
FT   VARIANT         173
FT                   /note="N -> S (in NEDSSWI; decreased deoxyhypusine synthase
FT                   activity; dbSNP:rs758100382)"
FT                   /evidence="ECO:0000269|PubMed:30661771"
FT                   /id="VAR_082649"
FT   VARIANT         174
FT                   /note="E -> D (in dbSNP:rs10425108)"
FT                   /id="VAR_043005"
FT   VARIANT         305..306
FT                   /note="Missing (in NEDSSWI; loss of deoxyhypusine synthase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:30661771"
FT                   /id="VAR_082650"
FT   MUTAGEN         106
FT                   /note="N->A: Strongly reduced NAD and spermidine binding.
FT                   Reduced activity."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         109
FT                   /note="S->A: Strongly reduced spermidine binding. Reduced
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         137
FT                   /note="E->A: Strongly reduced NAD binding. Strongly reduced
FT                   formation of covalent intermediate."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         238
FT                   /note="D->A: Strongly reduced NAD binding. Strongly reduced
FT                   formation of covalent intermediate."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         243
FT                   /note="D->A: Reduces spermidine binding by 98%. Strongly
FT                   reduced formation of covalent intermediate."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         287
FT                   /note="K->A: Reduces covalent intermediate formation and
FT                   deoxyhypusine synthesis by 99.5%. Retains low spermidine
FT                   cleavage activity."
FT                   /evidence="ECO:0000269|PubMed:9405486"
FT   MUTAGEN         288
FT                   /note="H->A: Reduces spermidine binding by 98%. Strongly
FT                   reduced NAD binding. Strongly reduced formation of covalent
FT                   intermediate."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         305
FT                   /note="Y->A: Strongly reduced NAD binding. No effect on
FT                   enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         313
FT                   /note="D->A: Strongly reduced NAD binding."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         316
FT                   /note="D->A: Reduces spermidine binding by 98%. Loss of
FT                   covalent intermediate formation and deoxyhypusine
FT                   synthesis."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         317
FT                   /note="S->A: Strongly reduced NAD binding. No effect on
FT                   enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         323
FT                   /note="E->A: Reduces spermidine binding by 98%. Strongly
FT                   reduced formation of covalent intermediate."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         327
FT                   /note="W->A: Reduces spermidine binding by 98%. Loss of
FT                   covalent intermediate formation and deoxyhypusine
FT                   synthesis."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   MUTAGEN         329
FT                   /note="K->A,R: Loss of covalent intermediate formation and
FT                   deoxyhypusine synthesis."
FT                   /evidence="ECO:0000269|PubMed:9405486"
FT   MUTAGEN         342
FT                   /note="D->A: Strongly reduced NAD binding. Strongly reduced
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11311149"
FT   CONFLICT        11
FT                   /note="A -> R (in Ref. 3; AAB02175/AAB02179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        13..14
FT                   /note="AL -> R (in Ref. 3; AAB02175/AAB02179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        85
FT                   /note="A -> G (in Ref. 3; AAB02175/AAB02179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        196
FT                   /note="T -> I (in Ref. 3; AAB02175/AAB02179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        199
FT                   /note="V -> A (in Ref. 3; AAB02175/AAB02179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        220
FT                   /note="V -> A (in Ref. 3; AAB02175/AAB02179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        228
FT                   /note="H -> K (in Ref. 11; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        296..297
FT                   /note="MR -> SG (in Ref. 3; AAB02179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        311
FT                   /note="E -> EE (in Ref. 3; AAB02179)"
FT                   /evidence="ECO:0000305"
FT   HELIX           11..17
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           36..38
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           42..47
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           48..51
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           54..73
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           81..88
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   STRAND          96..103
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           105..109
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           112..121
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   STRAND          126..130
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           132..140
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   TURN            141..143
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           155..160
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   STRAND          163..166
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   STRAND          169..172
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           173..196
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           203..214
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           220..226
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   TURN            234..237
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           240..251
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           260..271
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   STRAND          274..282
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           284..295
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   TURN            296..298
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   STRAND          300..307
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           311..313
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   TURN            316..318
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           321..327
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   STRAND          337..341
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           343..353
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   HELIX           355..358
FT                   /evidence="ECO:0007744|PDB:6XXJ"
FT   TURN            359..362
FT                   /evidence="ECO:0007744|PDB:6XXJ"
SQ   SEQUENCE   369 AA;  40971 MW;  5314FED620AC9EE7 CRC64;
     MEGSLEREAP AGALAAVLKH SSTLPPESTQ VRGYDFNRGV NYRALLEAFG TTGFQATNFG
     RAVQQVNAMI EKKLEPLSQD EDQHADLTQS RRPLTSCTIF LGYTSNLISS GIRETIRYLV
     QHNMVDVLVT TAGGVEEDLI KCLAPTYLGE FSLRGKELRE NGINRIGNLL VPNENYCKFE
     DWLMPILDQM VMEQNTEGVK WTPSKMIARL GKEINNPESV YYWAQKNHIP VFSPALTDGS
     LGDMIFFHSY KNPGLVLDIV EDLRLINTQA IFAKCTGMII LGGGVVKHHI ANANLMRNGA
     DYAVYINTAQ EFDGSDSGAR PDEAVSWGKI RVDAQPVKVY ADASLVFPLL VAETFAQKMD
     AFMHEKNED
//
